FindTrial
Sign In

The effect of Orlistat and Rosiglitazone on insulin action in a grouop of Chinese patients affected by the metabolic syndrome -- a randomized, single-blinded and placebo controlled study

The effect of Orlistat and Rosiglitazone on insulin action in a grouop of Chinese patients affected by the metabolic syndrome -- a randomized, single-blinded and placebo controlled study

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-09000652
Enrollment
Unknown
Registered
2005-09-09
Start date
2001-07-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gland and Hormone Related Diseases

Interventions

Two groups:Orlistat 1 year versus Rosiglitazone

Sponsors

None listed

Eligibility

Sex/Gender
Male
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients with impaired glucose tolerance or type 2 diabetes

Exclusion criteria

Exclusion criteria: Patients on insulin or requiring more than one diabetic medication

Design outcomes

Primary

MeasureTime frame
insulin action in patients with impaired glucose tolerance or type 2 diabetes;—

Secondary

MeasureTime frame
changes in cardiovascular risk factors;—

Countries

China

Contacts

Public ContactKenneth KC Lee
kclee@cuhk.edu.hk+852 26323377

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026